Ipamorelin vs CJC-1295: Comparing Two Growth Hormone Peptides

Disclaimer: This guide is for research and educational purposes only. It is not medical advice. These are research compounds not approved by the FDA for human use. Consult a licensed healthcare professional before using any injectable compound.

Ipamorelin and CJC-1295 are among the most frequently cited peptides in growth hormone axis research. They are often studied in combination — and for good reason. Despite frequently appearing together in research protocols, they work through distinct mechanisms. Understanding the difference is essential for any researcher working with either compound.

---

The Core Distinction: GHRP vs GHRH

The most important thing to understand about these two peptides is that they belong to entirely different peptide classes and trigger GH release through different pathways.

Ipamorelin: A GHRP (Growth Hormone Releasing Peptide)

Ipamorelin is a pentapeptide (5 amino acids) that acts as a selective agonist of the ghrelin receptor (also called the GH secretagogue receptor, or GHSR). By binding this receptor in the pituitary and hypothalamus, it stimulates the pituitary to release growth hormone.

Key characteristics established in research:

• Produces a pulsatile GH release pattern
• Highly selective — compared to other GHRPs (GHRP-2, GHRP-6), ipamorelin shows minimal stimulation of cortisol, prolactin, or ACTH
• Short half-life (approximately 2 hours)
• Does not strongly stimulate appetite (unlike GHRP-6, which notably increases ghrelin-related hunger signaling)

CJC-1295: A GHRH Analog (Growth Hormone Releasing Hormone)

CJC-1295 is a synthetic analog of growth hormone releasing hormone (GHRH), a hypothalamic peptide that naturally stimulates pituitary GH secretion. CJC-1295 is engineered to have a longer half-life than native GHRH (which degrades within minutes) through structural modifications.

Two versions are commonly referenced in research:

• CJC-1295 without DAC (also called Mod GRF 1-29): Half-life of approximately 30 minutes. Produces a pulsatile GH release when timed appropriately.
• CJC-1295 with DAC (Drug Affinity Complex): Modified to bind albumin in the bloodstream, extending half-life to approximately 6–8 days. Produces a more sustained elevation of GH.

---

Comparison Table

Feature	Ipamorelin	CJC-1295 (no DAC)	CJC-1295 with DAC
Class	GHRP (ghrelin receptor agonist)	GHRH analog	GHRH analog
Mechanism	Stimulates pituitary directly via GHSR	Mimics hypothalamic GHRH	Mimics GHRH with extended binding
Half-life	~2 hours	~30 minutes	~6–8 days
GH release pattern	Pulsatile	Pulsatile	Sustained/blunted pulsatility
Cortisol/prolactin effect	Minimal	Not a primary concern	Not a primary concern
Typical research dose	100–300 mcg	100 mcg	1–2 mg (less frequent)
Injection frequency	2–3x daily	2–3x daily	Once weekly

---

Why They Are Often Studied Together

The pituitary gland releases GH in response to signals from two pathways:

1. GHRH stimulation (from the hypothalamus)
2. Ghrelin receptor stimulation

When both pathways are activated simultaneously, research has demonstrated a synergistic amplification of the GH pulse — meaning the combined effect is substantially greater than either compound alone.

This is why ipamorelin and CJC-1295 (without DAC) are frequently studied in combination. Ipamorelin provides ghrelin-receptor stimulation while CJC-1295 provides GHRH-pathway stimulation. The combined injection is timed to coincide, allowing both signals to reach the pituitary simultaneously.

This combination approach is one of the most studied pairings in growth hormone axis peptide research.

---

Ipamorelin: Research Selectivity Advantage

Among GHRPs, ipamorelin stands out in preclinical literature for its selectivity. Earlier GHRPs (particularly GHRP-2 and GHRP-6) produced significant cortisol and prolactin elevations alongside GH release. These secondary hormonal effects were considered undesirable in research contexts.

Studies examining ipamorelin have consistently shown it produces GH release with minimal effect on cortisol, prolactin, or ACTH — a selectivity profile that makes it more suitable for isolated GH axis research where confounding hormonal effects should be minimized.

---

CJC-1295 DAC vs No DAC: Which for Research?

CJC-1295 without DAC (Mod GRF 1-29) is preferred when:

• Researchers want to observe pulsatile GH release
• Timing with ipamorelin injection is part of the protocol
• Closer physiological mimicry of natural GHRH pulse is the goal

CJC-1295 with DAC is studied when:

• Extended GH elevation over multiple days is the research objective
• Injection frequency reduction is a priority
• The protocol does not require precise pulse timing

The two versions have meaningfully different pharmacokinetics and should not be treated as interchangeable.

---

Reconstitution for Each

Both compounds follow standard peptide reconstitution with BAC water.

Ipamorelin (typical 2 mg vial)

Adding 2 mL BAC water to a 2 mg vial yields 1,000 mcg/mL.

• 100 mcg dose = 10 units on U-100 syringe
• 200 mcg dose = 20 units on U-100 syringe

CJC-1295 without DAC (typical 2 mg vial)

Adding 2 mL BAC water to a 2 mg vial yields 1,000 mcg/mL.

• 100 mcg dose = 10 units on U-100 syringe

CJC-1295 with DAC (typical 2 mg vial)

Same reconstitution — but dosing is less frequent. A 2 mg vial may last several weeks on a once-weekly protocol.

Use the main calculator for full dose-to-units calculations for any vial size and BAC water volume.

---

Frequently Asked Questions

Q: Can ipamorelin and CJC-1295 be drawn into the same syringe for injection? Some researchers combine both into a single syringe to reduce injection events. The compounds can be drawn sequentially into the same syringe. However, keep each peptide in its own reconstitution vial — do not combine them during reconstitution, only at the time of drawing.

Q: Does the order of drawing into the syringe matter? Draw ipamorelin first, then CJC-1295, or vice versa — consistency matters more than specific order. Total injection volume should be manageable (typically under 0.5 mL combined).

Q: Is CJC-1295 with DAC better than without DAC? "Better" depends on the research objective. With DAC provides convenience and sustained GH elevation but reduces the pulsatility that some research designs aim to study. Without DAC maintains physiological pulse patterns. Most combination protocols use CJC-1295 without DAC paired with ipamorelin.

Q: How long have these peptides been studied? CJC-1295 was first described in research literature in the early 2000s. Ipamorelin was developed slightly earlier. Human pharmacokinetic studies on CJC-1295 with DAC were published in 2006 (Teichman et al.). Ipamorelin has been studied in animal models and some human phase trials. Neither is FDA-approved for therapeutic use in the US.